Issue 7, 2022
From the journal:

RSC Chemical Biology

A dual-responsive doxorubicin–indoximod conjugate for programmed chemoimmunotherapy†

Zhaoxuan Yang,a   Jiaqi Huang,a   Yaying Lin,a   Xiangjie Luo,a   Haojin Lin,a   Hongyu Lin*a  and  Jinhao Gao ORCID logo *a  

* Corresponding authors

a Fujian Provincial Key Laboratory of Chemical Biology, The MOE Key Laboratory of Spectrochemical Analysis & Instrumentation, and Department of Chemical Biology, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China, China
E-mail: hylin007@xmu.edu.cn, jhgao@xmu.edu.cn

Abstract

Herein we report a dual-responsive doxorubicin–indoximod conjugate (DOXIND) for programmed chemoimmunotherapy. This conjugate is able to release doxorubicin and indoximod upon exposure to appropriate stimuli for synergistic chemotherapy and immunotherapy, respectively. We demonstrate its promoting effects on immune response and inhibiting effects on tumor growth through a series of in vitro and in vivo experiments.

Graphical abstract: A dual-responsive doxorubicin–indoximod conjugate for programmed chemoimmunotherapy

About
Cited by
Related
Download options Please wait...

Supplementary files

Article information

DOI
https://doi.org/10.1039/D1CB00257K
Article type
Communication
Submitted
29 Dec 2021
Accepted
29 May 2022
First published
30 May 2022
This article is Open Access
Creative Commons BY-NC license

RSC Chem. Biol., 2022,3, 853-858

Permissions

Request permissions

A dual-responsive doxorubicin–indoximod conjugate for programmed chemoimmunotherapy

Z. Yang, J. Huang, Y. Lin, X. Luo, H. Lin, H. Lin and J. Gao, RSC Chem. Biol., 2022, 3, 853 DOI: 10.1039/D1CB00257K

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements